severe atopic dermatitis
Recently Published Documents


TOTAL DOCUMENTS

1014
(FIVE YEARS 465)

H-INDEX

48
(FIVE YEARS 16)

Author(s):  
Andrew Blauvelt ◽  
Marjolein de Bruin-Weller ◽  
Eric L. Simpson ◽  
Zhen Chen ◽  
Marius Ardeleanu ◽  
...  

2022 ◽  
Vol 13 (1) ◽  
pp. 6-15
Author(s):  
Magdalini Kreouzi ◽  
Nikolaos Theodorakis ◽  
Ekatherine Prokopiou ◽  
Elena Thomaidou

Background: Adult atopic dermatitis (AD) is defined as a continuum of childhood AD or the development of the disease in adulthood, accounting for 7.7–59.7% of adult AD cases varying in severity and manifestations. The symptomatology of moderate-to-severe adult AD may significantly impact the overall health and quality of life of the patient. The “classic” topical treatments used in mild-to-moderate cases, such as emollients and topical corticosteroids, are usually not adequate to control the symptoms of most of the patients with moderate-to-severe disease. For many years these patients were managed with systemic corticosteroids and immunomodulators, leading to substantial side effects with questionable efficacy. The introduction of dupilumab, the first biologic agent approved by the Food and Drug Administration for use in adult moderate-to-severe AD, has commenced a new era in the management of AD. This narrative literature review addresses the question of how patients with moderate-to-severe AD may achieve a recession or improvement in the overall progression of the disease with the use of dupilumab in both an efficient and safe way. Material and Methods: A search in the PubMed, Embase, and Cochrane databases was conducted using the following combination of MeSH terms: “dupilumab” AND “atopic” (“dermatitis” OR “eczema”). The searches were limited to RCTs written in the English language published before January 25, 2021. The literature used included phase II and III RCTs examining the efficacy and/or safety of dupilumab compared to placebo or other treatments in adults with moderate-to-severe AD. Moderate-to-severe AD was defined by an IGA score of 3 (moderate) or 4 (severe) and EASI 16 or higher at screening and baseline. Additionally, we searched the website clinicaltrials.gov for any unpublished or ongoing RCTs. The search was done independently by two authors in all databases and followed by the exclusion of duplicates. Results: Upon reviewing all randomized controlled trials, dupilumab was found to be an effective and safe option for managing adult moderate-to-severe AD with long-term therapeutic effects. Conclusion: The best results for maintaining long-term disease recession were achieved with the combination of dupilumab and topical corticosteroids.


Author(s):  
Jonathan I. Silverberg ◽  
Norma P.M. Rubini ◽  
Mario C. Pires ◽  
Ana B. Rossi ◽  
Annie Zhang ◽  
...  

2021 ◽  
Vol 97 (5) ◽  
pp. 26-37
Author(s):  
A. E. Karamova ◽  
V. V. Chikin ◽  
A. A. Kubanov ◽  
L. K. Davletbaeva

One of the methods of therapy for atopic dermatitis is long-wavelength ultraviolet therapy A (UVA-1- therapy). This review aims to provide the mechanisms of action of UVA-1-therapy an overview about the effectiveness of UVA-1-therapy in patients with atopic dermatitis taking into account factors that can affect the effectiveness of treatment radiation dose, skin phototype of patients, concomitant drug therapy. The available data on a decrease in the severity of atopic dermatitis as a result of the course of UVA-1-therapy and on a decrease in the severity of itching in patients are presented. The data on the rate of onset of the therapeutic effect of UVA-1-therapy and the duration of its maintenance are considered. The safety of UVA-1-therapy is discussed, and the most frequent undesirable effects a feeling of warmth, fever, itching, hyperpigmentation, are given. The possibility of developing side effects requiring discontinuation of treatment is assessed. The data obtained indicate the effectiveness and safety of the UFA-1-radiation in the treatment of patients with moderate-to-severe atopic dermatitis.


Author(s):  
Jacob Mashiah ◽  
Tal Karady ◽  
Naomi Fliss‐Isakov ◽  
Eli Sprecher ◽  
Dan Slodownik ◽  
...  

Author(s):  
Kh. M. Vakhitov ◽  
I. N. Serdinskaya ◽  
T. G. Malanicheva

For 10 years the authors analyzed 165 clinical cases of children with atopic dermatitis, which manifested in the first year of life. According to the 10-year follow-up, the authors revealed different outcomes of the disease, depending on the severity of the course, clinical forms of dermatitis and the timing of its onset. Favorable outcome with complete remission was observed in 30.9% of cases and was more common in children with a mild course of atopic dermatitis, acute exudative forms and with the onset of the disease at the age over 6 months. The transition to chronic forms was noted in 14.5% of cases and more often took place in children with a moderate severe course of the disease, erythematous-squamous forms and the onset of the disease at the age of 4–6 months. The development of respiratory forms of allergy (allergic rhinitis and bronchial asthma) was noted in 54.6% of cases and was more often detected in patients with a moderate severe and severe atopic dermatitis, erythematous-squamous forms and exudative forms with lichenification and onset of the disease in the first 3 months of life.


Sign in / Sign up

Export Citation Format

Share Document